It may seem like science fiction: a trachea grown from stem cells and implanted into a human being. But it’s not; this is an actual account of the power of stem cells and regenerative medicine.
The 36-year-old patient, who had been suffering from late-stage tracheal cancer, received his new trachea in June at Karolinska University Hospital in Stockholm. The artificial trachea was made from a spongy plastic polymer scaffold scaled to the same dimensions as the patient’s trachea and then was seeded with the stem…
Uncertain Regulatory Environment
David Green. President, Harvard Biosciences, which provides tools to advance regenerative medicine. For more information, visit harvardbioscience.com.
Jeffrey Janus. Director, Senior VP, Operations, International Stem Cell Corp., and President and CEO of Lifeline Cell Technology, which are focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research products. For more information, visit internationalstemcell.com.
Sridar Natesan, Ph.D. Head of External Innovation and Partnering and Site Head for Cambridge, Sanofi, is a global and diversified healthcare company that discovers, develops, and distributes therapeutic solutions. For more information, visit sanofi.com.
Vivek R. Shinde Patil, Ph.D. Manager of Technical Applications, Caliper Life Sciences, a provider of tools and services for drug discovery and life-sciences research. For more information, visit caliperls.com.
Kelli Tanzella, Ph.D. Senior Manager Regulatory Affairs for the Americas, Life Technologies Corp., which manufactures molecular diagnostics. For more information, visit lifetechnologies.com.
Dean Tozer. Senior VP, Advanced BioHealing, which is now part of Shire, develops and commercializes living cell-based therapies that repair damaged human tissue and enable the body to heal itself. For more information, visit abh.com.